Newbury Pharmaceuticals AB (publ) (STO:NEWBRY)
Sweden · Delayed Price · Currency is SEK 2.400
-0.010 (-0.41%)
Sep 4, 2026, 12:49 PM CET
STO:NEWBRY Revenue
Newbury Pharmaceuticals AB had revenue of 8.93M SEK in the quarter ending May 31, 2026, with 33.61% growth. This brings the company's revenue in the last twelve months to 35.02M, down -25.14% year-over-year. In the fiscal year ending August 31, 2025, Newbury Pharmaceuticals AB had annual revenue of 31.57M, down -14.27%.
Revenue (ttm)
35.02M
Revenue Growth
-25.14%
P/S Ratio
2.08
Revenue / Employee
5.00M
Employees
7
Market Cap
72.95M
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Aug 31, 2025 | 31.57M | -5.26M | -14.27% |
| Aug 31, 2024 | 36.83M | 26.56M | 258.75% |
| Aug 31, 2023 | 10.27M | 4.75M | 86.11% |
| Aug 31, 2022 | 5.52M | 2.43M | 78.73% |
| Aug 31, 2021 | 3.09M | - | - |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Related Stocks
| Company Name | Revenue |
|---|---|
| EQL Pharma AB | 432.35M |
| Enzymatica AB | 51.93M |
| Cinclus Pharma Holding AB | 35.18M |
| Nanexa AB | 33.86M |
| Moberg Pharma AB | 16.76M |
| Orexo AB | 16.60M |
| Enorama Pharma AB | 1.45M |
| Dicot Pharma AB | 200.00K |
Newbury Pharmaceuticals AB News
- 1 month ago - Newbury Pharmaceuticals AB Quarterly report: Q3 2026 - Filings
- 4 months ago - Newbury Pharmaceuticals AB Quarterly report: Q2 2026 - Filings
- 5 months ago - Newbury Pharmaceuticals AB Slides: FY 2026 - Filings
- 7 months ago - Newbury Pharmaceuticals AB Quarterly report: Q1 2026 - Filings
- 10 months ago - Newbury Pharmaceuticals AB Annual report: Q4 2025 - Filings
- 10 months ago - Newbury Pharmaceuticals AB Quarterly report: Q4 2025 - Filings